What are the first‑line inhaler therapies for chronic obstructive pulmonary disease (COPD)?

First-Line Inhaler Therapies for COPD

The first-line inhaler therapy for COPD depends on symptom burden and exacerbation risk: patients with low symptoms should start with a single long-acting bronchodilator (LAMA or LABA), those with moderate-to-high symptoms should receive LAMA/LABA dual therapy, and patients at high risk of exacerbations with significant symptoms require LAMA/LABA/ICS triple therapy. 1

Treatment Algorithm Based on Clinical Presentation

Low Symptom Burden (CAT < 10, mMRC < 2)

• Start with a single long-acting bronchodilator (LABD) - either a LAMA or LABA 1
• Short-acting bronchodilators as needed should accompany all maintenance therapies 1
• This applies to patients with mildly impaired lung function (FEV1 ≥ 80% predicted) 1

Moderate-to-High Symptom Burden (CAT ≥ 10, mMRC ≥ 2)

• LAMA/LABA dual bronchodilator therapy is the recommended initial maintenance therapy 1
• This is preferred for patients with impaired lung function (FEV1 < 80% predicted) 1
• LAMA/LABA combination is superior to single bronchodilator therapy for symptom relief and health status improvement 1
• LAMA/LABA is preferred over ICS/LABA due to additional improvements in lung function and lower rates of adverse events such as pneumonia 1

High Exacerbation Risk with Significant Symptoms

• LAMA/LABA/ICS triple combination therapy is recommended 1
• High risk is defined as ≥2 moderate exacerbations or ≥1 severe exacerbation (requiring hospitalization/ED visit) in the past year 1
• Triple therapy should preferably be administered as single-inhaler triple therapy (SITT) rather than multiple inhalers 1
• The number needed to treat is 4 patients for 1 year to prevent one moderate-to-severe exacerbation with triple therapy versus dual bronchodilator therapy 1

Important Clinical Considerations

ICS-Containing Regimens

• ICS monotherapy has no role in COPD - ICS should only be used in combination with long-acting bronchodilators 1
• ICS/LABA may be first-choice initial therapy in patients with concomitant asthma or findings suggestive of asthma-COPD overlap 1
• High doses of ICS are not typically necessary - moderate doses provide optimal benefit with lower adverse effects 1
• The number needed to harm is 33 patients for 1 year to cause one pneumonia with ICS-containing therapy 1

Key Pitfalls to Avoid

• Do not use ICS as monotherapy - this is explicitly not recommended 1
• Avoid starting with ICS/LABA in typical COPD unless there is concomitant asthma, as LAMA/LABA provides better outcomes with fewer side effects 1
• Do not use oral corticosteroids for maintenance therapy - they have no evidence of benefit and numerous side effects 1
• Be aware that ICS increases pneumonia risk, particularly in patients who currently smoke, are aged ≥55 years, have prior exacerbations/pneumonia history, BMI <25 kg/m², or severe airflow limitation 1

Specific GOLD Group Recommendations (2017 Framework)

Group A (Low symptoms, low risk):

• Single long-acting bronchodilator (LAMA or LABA) 1

Group B (High symptoms, low risk):

• Initial therapy with a long-acting bronchodilator 1
• For persistent breathlessness on monotherapy, use two bronchodilators (LAMA/LABA) 1

Group D (High symptoms, high risk):

• LAMA/LAMA combination is the recommended initial therapy 1
• LAMA/LABA was superior to ICS/LABA in preventing exacerbations and improving patient-reported outcomes 1
• If single bronchodilator chosen initially, LAMA is preferred over LABA for exacerbation prevention 1

Mortality Benefit Considerations

• Moderate-dose ICS in triple therapy demonstrated mortality benefit compared to low-dose ICS in the ETHOS study 1
• This mortality benefit must be balanced against the increased pneumonia risk with ICS-containing regimens 1